Brought to you by 
Renovis acquires assets from Centaur Pharmaceuticals
03 Feb 2003
Executive Summary
In an effort to accelerate its drug discovery and add more advanced product candidates to its development program, Renovis (founded 2000; neuropharmaceuticals) will acquire all of Centaur Pharmaceuticals' (developing drugs to treat primarily neurodegenerative disorders) compounds, including two Phase II and several preclinical CNS products, and all intellectual property related to the compounds.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Renovis acquires assets from Centaur Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice